ClinicalTrials.gg
CompletedNCT06816043Updated Jun 27, 2025

A Study of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and MK-8527 in Healthy Participants

A Phase 1 interventional study of MK-8527 and FTC/TDF in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-27.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

The goal of this study is to learn what happens to MK-8527 in a healthy person's body over time, called a pharmacokinetic (PK) study. Researchers want to learn if there is a difference in the healthy person's body when MK-8527 is taken as a single dose (Treatment A) or with the medication Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) (Treatment B).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior
  • Has (BMI) ≥18 and ≤32.0 kg/m\^2

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • History of low bone density, renal impairment, Fanconi syndrome, disorders (such as Graves' disease, polymyositis, Guillain-Barré syndrome, and autoimmune hepatitis), liver disease
  • History of cancer ()
  • Positive results for (HIV), surface antigen (HBsAg), or virus (HCV)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Treatment A: MK-8527

    Participants receive a single dose of MK-8527.

    Drug: MK-8527

  • Experimental
    Treatment B: MK-8527 + FTC/TDF

    Participants receive FTC/TDF then MK-8527.

    Drug: MK-8527 · Drug: FTC/TDF

Interventions

  • Oral Capsule

  • DrugFTC/TDF

    Oral Tablet

    Also known as: emtricitabine/tenofovir disoproxil fumarate

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve from Time 0 to Infinity after single dosing (AUC0-Inf) of MK-8527-Triphosphate (TP) in peripheral blood mononuclear cell (PBMC)

    Blood samples will be collected to determine the AUC0-Inf of MK-8527-TP in PBMC.

    Time frame: Pre-dose and at designated time points up to 840 hours post dose

  2. Area Under the Concentration-Time Curve from Time 0 to Last quantifiable sample (AUC0-last) of MK-8527-TP in PBMC

    Blood samples will be collected to determine the AUC0-last of MK-8527-TP in PBMC.

    Time frame: Pre-dose and at designated time points up to 840 hours post dose

  3. Drug Concentration at 672 Hours (C672) of MK-8527-TP in PBMC

    Blood samples will be collected to determine the C672 of MK-8527-TP in PBMC.

    Time frame: Pre-dose and at designated time points up to 672 hours post dose

  4. Maximum Plasma Concentration (Cmax) of MK-8527-TP in PBMC

    Blood samples will be collected to determine the Cmax of MK-8527-TP in PBMC.

    Time frame: Pre-dose and at designated time points up to 840 hours post dose

  5. Time to Maximum Plasma Concentration (Tmax) of MK-8527-TP in PBMC

    Blood samples will be collected to determine the Tmax of MK-8527-TP in PBMC.

    Time frame: Pre-dose and at designated time points up to 840 hours post dose

  6. Apparent Terminal Half-life (t1/2) of MK-8527-TP in PBMC

    Blood samples will be collected to determine the t1/2 of MK-8527-TP in PBMC.

    Time frame: Pre-dose and at designated time points up to 840 hours post dose

Secondary outcomes

  1. AUC0-Inf of MK-8527 in plasma

    Blood samples will be collected to determine the AUC0-Inf of MK-8527 in plasma.

    Time frame: Pre-dose and at designated time points up to 120 hours post dose

  2. AUC0-last of MK-8527 in plasma

    Blood samples will be collected to determine the AUC0-last of MK-8527 in plasma.

    Time frame: Pre-dose and at designated time points up to 120 hours post dose

  3. Cmax of of MK-8527 in plasma

    Blood samples will be collected to determine the Cmax of MK-8527 in plasma.

    Time frame: Pre-dose and at designated time points up to 120 hours post dose

  4. Tmax of MK-8527 in plasma

    Blood samples will be collected to determine the Tmax of MK-8527 in plasma.

    Time frame: Pre-dose and at designated time points up to 120 hours post dose

  5. t1/2 of MK-8527 in plasma

    Blood samples will be collected to determine the t1/2 of MK-8527 in plasma.

    Time frame: Pre-dose and at designated time points up to 120 hours post dose

  6. Apparent Clearance (CL/F) of MK-8527 in plasma

    Blood samples will be collected to determine the CL/F MK-8527 in plasma

    Time frame: Pre-dose and at designated time points up to 120 hours post dose

  7. Apparent volume of distribution during terminal phase (Vz/F) of MK-8527 in plasma

    Blood samples will be collected to determine the Vz/F of MK-8527 in plasma

    Time frame: Pre-dose and at designated time points up to 120 hours post dose

  8. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 111 days

  9. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.

    Time frame: Up to approximately 43 days

07

Study locations

1 site
  • Celerion ( Site 0001)
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in Jun 2025, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2025
First posted
Feb 10, 2025
StartActual
Feb 21, 2025
Primary completionActual
Jun 5, 2025
CompletionActual
Jun 17, 2025
Last update
Jun 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06816043
Responsible party
Sponsor
First posted
Feb 10, 2025
Start date
Feb 21, 2025
Primary completion
Jun 5, 2025
Completion
Jun 17, 2025
Last update
Jun 27, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alimatravir

Start the discussion